Concepedia

Taishi Sakatani

TS

8

Publications

167

Citations

8

H-Index

2018

Active since

Affiliations

Astellas Pharma (Japan)(Current)

Kawasaki Medical School

Astellas Pharma (United States)

Taishi Sakatani is an author at Astellas Pharma (Japan).

Publications per year

2018–2024

8

Publications

8

Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial

Kohei Kaku, Hiroyuki Isaka, Taishi Sakatani et al. · Diabetes Obesity and Metabolism · 2019 · 46 citations · Full text

Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial

Kyung‐Ah Han, Suk Chon, Choon Hee Chung et al. · Diabetes Obesity and Metabolism · 2018 · 41 citations · Full text

Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials

Atsunori Kashiwagi, Taishi Sakatani, Ichiro Nakamura et al. · Endocrine Journal · 2018 · 16 citations · Full text

Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo‐controlled trial

Kohei Kaku, Hiroyuki Isaka, Junko Toyoshima et al. · Diabetes Obesity and Metabolism · 2019 · 15 citations · Full text

Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study

Hisamitsu Ishihara, Susumu Yamaguchi, Ikko Nakao et al. · Diabetes Therapy · 2018 · 14 citations · Full text

Rows per page

1–5 of 8